Hangzhou Sciwind Biosciences Co. has signed a licensing and collaboration agreement for the global development and commercialization of a portfolio of metabolic diseases therapies in territories outside of Greater China and South Korea, with Verdiva Bio Ltd.

Sciwind has granted Verdiva the exclusive global rights to develop, manufacture and commercialize the partnered programs outside of greater China and South Korea. Sciwind has retained the rights to develop, manufacture and commercialize these products in all other regions.

Under the agreement, Sciwind receives an upfront consideration totaling approximately USD 70 million, and is eligible to receive more than USD 2.4 billion in milestone payments for development, regulatory approvals and commercialization of above-mentioned partnered programs.

Additionally, Sciwind is also eligible to receive tiered royalties on future product sales outside of greater China and South Korea. Furthermore, the two companies will collaborate on additional preclinical stage programs, and Sciwind is eligible to receive milestones and royalty payments based on the advancement of those programs.

Verdiva Bio, led by industry experts and serial entrepreneurs, boasts a world-class drug development team with extensive experience in the global metabolic treatment sector. With this collaboration, Verdiva Bio plans to advance the development of innovative therapies through a series of clinical studies involving both monotherapy and combination treatments.

This collaboration highlights the global commercialization potential of Sciwind's innovative pipeline and lays a solid foundation for the worldwide development and potential commercialization of key products like Ecnoglutide.